Earnings per share for the last twelve months: Olema Corp (OLMA)

Olema Pharmaceuticals (OLMA) is developing innovative molecules for the complete blockade of estrogen receptors, aiming for market dominance. The company's TTM EPS trend on the precise GURU.Markets chart confirms that the -2.33 mark is a current indicator. The business relies on proprietary targeted therapy protocols, and its advanced drug pipeline is currently completing the clinical trial stage.
Analytical breakdowns for Olema Corp (OLMA)

For the biopharmaceutical brand Olema Pharmaceuticals (OLMA), which is developing innovative methods to combat breast cancer, the annual net income per share trend serves as an indicator of the efficiency of monetizing scientific achievements. This metric is calculated by dividing the total net profit over the last 12 months by the number of shares, allowing the investor to assess the real return on capital and distinguish fundamental business growth from short-term speculative fluctuations.